Table 1.
Visita | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 |
Day/month after first challenge | 0 | 2 | 4 | 7 | 14 | 21 | 28 | 30 | 32 | 35 | 42 | 49 | 51 | 53 | 56 | 63 | 70 | 74 | 6 months | 9 months | 12 months |
BCG challenge | X | X | X | ||||||||||||||||||
PAXGeneb | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x | x |
Arraysc | X | X | X | X | X | X | X | X | X | X | X | X | |||||||||
CMId | X | X | X | X | X | X | X |
Study visit 14 was omitted.
Samples of blood taken into PAXGene tubes, RNA extracted and analysis of content and purity performed for these time points.
Analysis of RNA by Illumina microarray performed for these time points.
PBMCs separated and in vitro culture for IFNγ secretion in response to antigen stimulation performed for these time points.